HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports.

A number of other equities analysts have also recently issued reports on ESPR. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.30.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $2.34 on Friday. The stock has a market capitalization of $461.07 million, a price-to-earnings ratio of -3.66 and a beta of 1.01. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The stock’s 50 day moving average price is $2.46 and its two-hundred day moving average price is $2.18.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ESPR. Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics in the third quarter valued at about $606,000. Anson Funds Management LP bought a new stake in shares of Esperion Therapeutics in the third quarter valued at $540,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Esperion Therapeutics by 71.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after acquiring an additional 295,378 shares during the period. Wellington Management Group LLP increased its holdings in Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after acquiring an additional 241,512 shares during the last quarter. Finally, Wasatch Advisors LP raised its stake in Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after acquiring an additional 6,483,070 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.